A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In this trial of the treatment of newly diagnosed multiple myeloma, we compared a protocol that entailed a hematopoietic stem-cell autograft followed by an allograft from an HLA-identical sibling with a protocol of tandem autografts. METHODS: We enrolled 162 consecutive patients with newly diagnosed myeloma who were 65 years of age or younger and who had at least one sibling. All patients were initially treated with vincristine, doxorubicin, and dexamethasone, followed by melphalan and autologous stem-cell rescue. Patients with an HLA-identical sibling then received nonmyeloablative total-body irradiation and stem cells from the sibling. Patients without an HLA-identical sibling received two consecutive myeloablative doses of melphalan, each of which was followed by autologous stem-cell rescue. The primary end points were overall survival and event-free survival. RESULTS: After a median follow-up of 45 months (range, 21 to 90), the median overall survival and event-free survival were longer in the 80 patients with HLA-identical siblings than in the 82 patients without HLA-identical siblings (80 months vs. 54 months, P=0.01; and 35 months vs. 29 months, P=0.02, respectively). Among patients who completed their assigned treatment protocols, treatment-related mortality did not differ significantly between the double-autologous-transplant group (46 patients) and the autograft-allograft group (58 patients, P=0.09), but disease-related mortality was significantly higher in the double-autologous-transplant group (43% vs. 7%, P<0.001). The cumulative incidence rates of grades II, III, and IV graft-versus-host disease (GVHD) combined and of grade IV GVHD in the autograft-allograft group were 43% and 4%, respectively. Overall, 21 of 58 patients (36%) were in complete remission after a median follow-up of 38 months (range, 10 to 72) after allografting. Of the 46 patients who received two autografts, 25 (54%) died. CONCLUSIONS: Among patients with newly diagnosed myeloma, survival in recipients of a hematopoietic stem-cell autograft followed by a stem-cell allograft from an HLA-identical sibling is superior to that in recipients of tandem stem-cell autografts. (ClinicalTrials.gov number, NCT00415987 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The role of allogeneic and non-myeloablative-allogeneic transplantation in multiple myeloma is controversial with studies showing conflicting results.138–140”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [139]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
1994 Consensus Conference on Acute GVHD Grading.
Przepiorka, D., Weisdorf, D., Martin, P., Hg, K., Beatty, P., Hows, J., & Thomas, E. D. (1995) · PubMed · Cited by 5,037
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Szer, J. (1999) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1999.tb127745.x · Cited by 3,353
International Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
Self-citationGooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Research works printed but not linked: 1
- Sullivan KM, 1991, Semin Hematol, 28, 250
Cited by
Items 201–300 of 503
Cellular immunotherapy for multiple myeloma
Rosenblatt, J. M., & Avigan, D. (2008) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2008.07.007 · Cited by 19
Karlin, L., Arnulf, B., Chevret, S., Adès, L., Robin, M., de Latour, R. P., Malphettes, M., Kabbara, N., Asli, B., Rocha, V., et al. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.90 · Cited by 19
Hematopoietic Stem Cell Transplantation
Im, A., & Pavletic, S. Z. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00028-1 · Cited by 19
How to treat a newly diagnosed young patient with multiple myeloma
Miguel, J. F. S., & Mateos, M. (2009) · Hematology · doi:10.1182/asheducation-2009.1.555 · Cited by 21
Leaf, R. K., Cho, H. J., & Avigan, D. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0283-0 · Cited by 19
Montefusco, V., Mussetti, A., Rezzonico, F., Maura, F., Pennisi, M., Philippis, C. D., Capecchi, M., & Corradini, P. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.183 · Cited by 18
Ayuk, F., Pérez‐Simón, J. A., Shimoni, A., Sureda, A. M., Zabelina, T., Schwerdtfeger, R., Martino, R., Sayer, H. G., Alegre, A. M., Lahuerta, J. J., et al. (2008) · Haematologica · doi:10.3324/haematol.12665 · Cited by 18
“60 (at 1 year) Leukocyte engraftment (range) 13 days (6-21) 16 days (9-23) <0.”
InfluentialAdvances in the Autologous and Allogeneic Transplantation Strategies for Multiple Myeloma
Nishihori, T., & Alsina, M. (2011) · Cancer Control · doi:10.1177/107327481101800406 · Cited by 20
Death of frontline allo-SCT in myeloma
Moreau, P. (2012) · Blood · doi:10.1182/blood-2012-04-420802 · Cited by 17
Allogeneic transplantation in multiple myeloma
Gahrton, G., & Krishnan, A. Y. (2013) · Expert Review of Hematology · doi:10.1586/17474086.2014.857270 · Cited by 17
“Based on canine transplant studies [29], the Seattle Group attempted to find a balance of the minimal conditioning needed to achieve allogeneic engraftment [30].”
BackgroundMcCarthy, P. L., Einsele, H., Attal, M., & Giralt, S. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.878645 · Cited by 17
“Among the six trials comparing tandemauto–alloHSCT and tandem or single AHSCT are two showing a significant advantage of the allogeneic arm [31,36]; these are the studies with the longest follow-up.”
BackgroundRole of stem cell transplant and maintenance therapy in plasma cell disorders
McCarthy, P. L., & Holstein, S. A. (2016) · Hematology · doi:10.1182/asheducation-2016.1.504 · Cited by 18
Ghosh, N., Ye, X., Tsai, H., Bolaños‐Meade, J., Fuchs, E. J., Luznik, L., Swinnen, L. J., Gladstone, D. E., Ambinder, R. F., Varadhan, R., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.07.003 · Cited by 17
López‐Corral, L., Caballero‐Velázquez, T., López‐Godino, O., Rosiñol, L., Pérez-Vicente, S., Fernández‐Avilés, F., Krsnik, I., Morillo, D., Heras, I. D. L., Morgades, M., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.04.026 · Cited by 18
Levenga, H., Levison-Keating, S., Schattenberg, A. V. M. B., Dolstra, H., Schaap, N. P., & Raymakers, R. A. P. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705742 · Cited by 17
Nishihori, T., Ochoa-Bayona, J. L., Kim, J., Pidala, J., Shain, K. H., Baz, R., Sullivan, D. M., Jim, H., Anasetti, C., & Alsina, M. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.37 · Cited by 17
Koehne, G., & Giralt, S. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328358f619 · Cited by 19
Hematopoietic Stem Cell Transplantation in Multiple Myeloma
Harousseau, J. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0063 · Cited by 17
Vogl, D. T., Liu, S. V., Chong, E. A., Luger, S. M., Porter, D. L., Schuster, S. J., Tsai, D. E., Perl, A. E., Loren, A. W., Goldstein, S. C., et al. (2007) · American Journal of Hematology · doi:10.1002/ajh.21038 · Cited by 16
Nikolaenko, L., Chhabra, S., Biran, N., Chowdhury, A., Hari, P., Krishnan, A. Y., & Richter, J. R. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.01.010 · Cited by 17
Hematopoietic Stem Cell Transplantation
Bishop, M. R., & Pavletic, S. Z. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50036-1 · Cited by 16
A procedure for identifying stem cell compartments with multi-lineage differentiation potential
Amin, H. D., Olsen, I., Knowles, J. C., & Donos, N. (2011) · The Analyst · doi:10.1039/c0an00816h · Cited by 15
Gran, C., Wang, J., Nahi, H., Köster, L., Gahrton, G., Einsele, H., Niittyvoupio, R., Edinger, M., Beelen, D. W., Ciceri, F., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16642 · Cited by 15
Gagelmann, N., Eikema, D.-J., de Wreede, L. C., Rambaldi, A., Iacobelli, S., Köster, L., Caillot, D., Blaise, D., Remémyi, P., Bulabois, C., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01007-w · Cited by 16
“Allogeneic stem cell transplantation has been proposed as a treatment for younger and fit patients at high risk, but data on the impact of this approach specifically in patients with cytogenetic abnormalities are scarce [28].”
BackgroundSelf-citationPawarode, A., Mineishi, S., Reddy, P. R., Braun, T., Khaled, Y. A., Choi, S. W., Magenau, J. M., Harris, A. C., Connelly, J. A., Kitko, C. L., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.07.021 · Cited by 16
“The use of upfront tandem reduced-intensity related donor Allo-HCT after Auto-HCT in early-stage MM may be associated with improved progression-free survival (PFS) over single or tandem Auto-HCTs in high-risk MM, but it is not consistently in standard-risk disease [26-32].”
BackgroundManagement of Newly Diagnosed Myeloma
Rajkumar, S. V., & Palumbo, A. P. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.08.008 · Cited by 17
Self-citationMultiple myeloma: the disease and its treatment
Gupta, M., Pal, R. N., & Tikoo, D. (2013) · International Journal of Basic & Clinical Pharmacology · doi:10.5455/2319-2003.ijbcp20130302 · Cited by 17
Hämatopoetische Stammzelltransplantation
Buchholz, S., & Ganser, A. (2009) · Der Internist · doi:10.1007/s00108-008-2273-y · Cited by 15
Stem cell transplantation for multiple myeloma: current and future status
Giralt, S., & Bensinger, W. (2013) · Leukemia Supplements · doi:10.1038/leusup.2013.3 · Cited by 14
Sahebi, F., Iacobelli, S., van Biezen, A., Volin, L., Dreger, P., Michallet, M., Ljungman, P. T., de Witte, T., Henseler, A., Schaap, N. P., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.45 · Cited by 14
The role of tandem stem cell transplantation for multiple myeloma patients
Martino, M. V., Recchia, A. G., Fedele, R., Neri, S., Vincelli, I. D., Moscato, T., Gentile, M., & Morabito, F. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1136285 · Cited by 16
“OS benefit with an ASCT/alloSCT approach was limited to studies using 2 Gy TBI-based conditioning regimens,[76] which had led to speculation [73] that the lack of survival benefit in other studies could be related to the use of more intense conditioning that is associated with increased regimen-related toxicity and mo…”
BackgroundMethodResultInfluentialLong-term outcome after allogeneic stem cell transplantation in multiple myeloma
Luoma, S., Silvennoinen, R. H., Rauhala, A., Niittyvuopio, R., Martelin, E., Lindström, V., Heiskanen, J., Volin, L., Ruutu, T., & Nihtinen, A. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04514-y · Cited by 14
“In our study, the RI curve seemed to form a plateau at 10–15 years, indicating that 20–25% of the patients achieve long-term remission, as seen in previous studies with a long follow-up [3, 6, 8].”
BackgroundResultHarousseau, J. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705810 · Cited by 15
Drug-Mediated and Cellular Immunotherapy in Multiple Myeloma
Ritchie, D. S., Quach, H., Fielding, K., & Neeson, P. J. (2010) · Immunotherapy · doi:10.2217/imt.10.9 · Cited by 14
Beaussant, Y., Daguindau, É., Pugin, A., Mohty, M., Avet‐Loiseau, H., Roos‐Weil, D., Michallet, M., Chevalier, P., Raus, N., Cheikh, J. E., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.04.020 · Cited by 14
“However, studies that compared RIC versus autoSCT as first-line treatment, particularly in the tandem autoSCT/alloSCT setting, have yielded conflicting results [16-21].”
BackgroundResultDiagnosis and the current trends in multiple myeloma therapy
Dmoszyńska, A. (2008) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.490 · Cited by 14
Stem Cell Transplantation in Multiple Myeloma
Attal, M., Moreau, P., Avet‐Loiseau, H., & Harousseau, J. (2007) · Hematology · doi:10.1182/asheducation-2007.1.311 · Cited by 17
Takimoto, M., Ogawa, K., Kato, Y., SAITO, T., Suzuki, T., Irei, M., Shibuya, Y., Suzuki, Y., Kato, M., Inoue, Y., et al. (2008) · International Journal of Hematology · doi:10.1007/s12185-008-0039-x · Cited by 13
“non-myeloablative allogenic SCT [4–6].”
Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle
Malek, E., El‐Jurdi, N., Kröger, N. M., & Lima, M. J. G. D. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00287 · Cited by 13
“(47) All patients MRD TBI 2 Gy CSA + MMF 2/10h 26/55 29/35 54/80”
Light Chains: Heavy Burden in Kidney Transplantation
Heher, E. C., Spitzer, T. R., & Goes, N. B. (2009) · Transplantation · doi:10.1097/tp.0b013e31819b9977 · Cited by 12
“High treatmentrelated mortality has limited its application, but new approaches which combine autologous with nonmyeloablative (“mini”) allogeneic transplant seem promising (5, 18, 36).”
BackgroundInamoto, Y., Kurahashi, S., Imahashi, N., Fukushima, N., Adachi, T., Kinoshita, T., Tsushita, K., Miyamura, K., Naoe, T., & Sugiura, I. (2009) · American Journal of Hematology · doi:10.1002/ajh.21390 · Cited by 13
“In addition, along with recent decreased nonrelapse mortalities, the curative potential of allogeneic hematopoietic stem cell transplantation is of increasing interest [19,20].”
BackgroundImmunotherapeutic approaches to treat multiple myeloma
Roeven, M. W. H., Hobo, W. A., Schaap, N. P., & Dolstra, H. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.27380 · Cited by 13
“The first was performed by the Italian GIMEMA group and found a median OS of 80 mo in 80 patients in the allogeneic SCT group compared with 54 mo in 82 patients in the autologous SCT group.(37) In addition the EBMT observed improved OS after 6 y in 108 patients who underwent autologous/allogeneic SCT (auto/alloSCT) co…”
ResultAllogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work
Bashir, Q., & Qazilbash, M. H. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0374-1 · Cited by 15
Is there still a role for allogeneic stem-cell transplantation in multiple myeloma?
Bensinger, W. (2007) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2007.09.007 · Cited by 13
Treatment of Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients
Kumar, S. K. (2011) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-011-0083-0 · Cited by 15
“In the Italian trial, 108 patients younger than 65 years of age with newly diagnosed MM received standard SCT, followed by low-dose total body irradiation conditioning and HLA-matched sibling allo-SCT or a second ASCT [ 45 ].”
BackgroundQuach, H., Joshua, D. E., Ho, J., Szer, J., Spencer, A. G., Harrison, S. J., Mollee, P. N., Roberts, A. W., Horvath, N., Talulikar, D., et al. (2015) · Internal Medicine Journal · doi:10.1111/imj.12640 · Cited by 17
Allogeneic transplantation in multiple myeloma
Gahrton, G., & Björkstrand, B. (2008) · Haematologica · doi:10.3324/haematol.13555 · Cited by 13
“One of them, published by Bruno et al.14, showed a superior overall survival for patients who underwent autologous-allogeneic transplantation.”
BackgroundResultInfluentialEngineering Antitumor Immunity by T-Cell Adoptive Immunotherapy
Riddell, S. R. (2007) · Hematology · doi:10.1182/asheducation-2007.1.250 · Cited by 13
Treatment of newly diagnosed multiple myeloma: advances in current therapy
Kumar, S. K. (2009) · Medical Oncology · doi:10.1007/s12032-009-9370-1 · Cited by 13
“In an Italian trial, 108 patients younger than 65 years of age with newly diagnosed MM received standard SCT, followed by low-dose total body irradiation (TBI) conditioning and HLA-matched sibling allo-SCT or a second ASCT [52].”
BackgroundCurrent Approaches to the Initial Treatment of Symptomatic Multiple Myeloma
Jasielec, J. K., & Jakubowiak, A. J. (2013) · International Journal of Hematologic Oncology · doi:10.2217/ijh.13.3 · Cited by 13
Biernacki, M. A., Tai, Y., Zhang, G., Alonso, A., Zhang, W., PRABHALA, R. H., Zhang, L., Munshi, N. C., Neuberg, D. S., Soiffer, R. J., et al. (2012) · Blood · doi:10.1182/blood-2011-11-388926 · Cited by 12
Strategies for Risk-Adapted Therapy in Myeloma
Fonseca, R. (2007) · Hematology · doi:10.1182/asheducation-2007.1.304 · Cited by 15
Mir, M. A., Kapoor, P., Kumar, S. K., Pandey, S., Dispenzieri, A. A., Lacy, M. Q., Dingli, D., Hogan, W. J., Buadi, F. K., Hayman, S. R., et al. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.03.016 · Cited by 12
Myeloma Kidney: Improving Clinical Outcomes?
Haynes, R., Leung, N., Kyle, R. A., & Winearls, C. G. (2012) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2012.03.001 · Cited by 12
Oncology: Treatment of Multiple Myeloma in the Targeted Therapy Era
Saad, A. A., Sharma, M. R., & Higa, G. M. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l428 · Cited by 13
Hayden, P. J., Iacobelli, S., Pérez‐Simón, J. A., van Biezen, A., Minnema, M. C., Niittyvuopio, R., Schönland, S. O., Meijer, E., Blaise, D., Milpied, N. J., et al. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13352 · Cited by 14
Krishnan, A. Y., Vij, R., Keller, J., Dhakal, B., & Hari, P. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159016 · Cited by 12
Quach, H., Joshua, D., Ho, J., Szer, J., Spencer, A. G., Harrison, S. J., Mollee, P. N., Roberts, A. W., Horvath, N., Talaulikar, D., et al. (2015) · Internal Medicine Journal · doi:10.1111/imj.12688 · Cited by 13
Long‐term survival after allogeneic stem cell transplantation for advanced stage multiple myeloma
Vekemans, M., Michaux, L., Neste, E. V. D., & Ferrant, A. (2014) · British Journal of Haematology · doi:10.1111/bjh.12881 · Cited by 11
Lokhorst, H. M., van der Holt, B., Cornelissen, J. J., Kersten, M. J., van Oers, M. H. J., Raymakers, R. A. P., Minnema, M. C., Zweegman, S., Bos, G. M. J., Schaap, N. P., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.128728 · Cited by 12
“Results of Allogeneic Stem Cell Transplantation (AlloSCT) as part of first-line therapy for multiple myeloma (MM) are conflicting.(1-7) The 96 month long-term followup of the EBMT trial showed a significantly prolonged PFS and OS for Auto-/Allo-SCT as compared to double Auto-SCT, both in the intention-to-treat analysi…”
Byrne, M. T., Wingard, J. R., & Moreb, J. S. (2013) · Transplantation Proceedings · doi:10.1016/j.transproceed.2013.03.054 · Cited by 11
Non‐myeloablative conditioning and allogeneic transplantation for multiple myeloma
Osman, K., Elliott, B., Mandeli, J., Scigliano, E., Malone, A. K., Isola, L. M., & Grosskreutz, C. L. (2010) · American Journal of Hematology · doi:10.1002/ajh.21633 · Cited by 11
Boosting Immunity against Multiple Myeloma
Lopes, R., Ferreira, B. V., Caetano, J., Barahona, F., Carneiro, E. A., & Joao, C. M. (2021) · Cancers · doi:10.3390/cancers13061221 · Cited by 12
Arnason, J. E., & Avigan, D. (2012) · Immunotherapy · doi:10.2217/imt.12.118 · Cited by 11
Samaras, P., Bargetzi, M. J., Betticher, D. C., Duchosal, M. A., Heim, D. A., Hess, U., Ketterer, N., Lerch, E., Matthes, T., Mey, U., et al. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14100 · Cited by 11
Cellular therapy following allogeneic stem-cell transplantation
Rager, A., & Porter, D. (2011) · Therapeutic Advances in Hematology · doi:10.1177/2040620711412416 · Cited by 10
“There is an important graft-versus-myeloma (GVM) effect associated with allogeneic HSCT [Badros et al. 2001; Bjorkstrand et al. 1996; Bruno et al. 2007].”
BackgroundIn pursuit of the allo-immune response in multiple myeloma: where do we go from here?
Cook, G., Bird, J. M., & Marks, D. I. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.397 · Cited by 10
Fabre, C., Koscielny, S., Mohty, M., Fégueux, N., Blaise, D., Maillard, N., Tabrizi, R., Michallet, M., Socié, G., Yakoub‐Agha, I., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.049742 · Cited by 13
“Time since diagnosis (months) 8; range [2-340]”
Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma
Laubach, J. P., & Kumar, S. K. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40320-5_9 · Cited by 10
Knop, S. T., Langer, C., Engelhardt, M. M., Mügge, L.-O., Reichle, A., Rösler, W., Bassermann, F. C., Hertenstein, B., Kunitz, A., Röllig, C., et al. (2017) · Leukemia · doi:10.1038/leu.2017.124 · Cited by 10
Schneidawind, C., Duerr‐Stoerzer, S., Faul, C., Kanz, L., Weisel, K. C., Bethge, W. A., & Schneidawind, D. (2017) · Clinical Transplantation · doi:10.1111/ctr.12994 · Cited by 11
Autologous Stem Cell Transplantation for Chronic Lymphocytic Leukemia
Dreger, P., Brand, R., & Michallet, M. (2007) · Seminars in Hematology · doi:10.1053/j.seminhematol.2007.08.008 · Cited by 10
Resche‐Rigon, M., Pirracchio, R., Robin, M., de Latour, R. P., Sibon, D., Adès, L., Ribaud, P., Fermand, J., Thiéblemont, C., Socié, G., et al. (2012) · BMC Blood Disorders · doi:10.1186/1471-2326-12-10 · Cited by 9
“Months to relapse 17 [13-33] 24 [17-32] 0.”
When to recommend allogeneic transplant in multiple myeloma
Gertz, M. A. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1052808 · Cited by 9
Samaras, P., Blickenstorfer, M., Haile, S. R., Siciliano, D., Petrausch, U., Mischo, A., Zweifel, M., Honegger, H., Schanz, U., Stüssi, G., et al. (2011) · Swiss Medical Weekly · doi:10.4414/smw.2011.13203 · Cited by 12
Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting
Solimando, A. G., Krebs, M., Desantis, V., Marziliano, D., Caradonna, I. C., Morizio, A., Argentiero, A., Shahini, E., & Bittrich, M. (2023) · Biomedicines · doi:10.3390/biomedicines11072087 · Cited by 13
“In a randomized study, conducted in the era before the introduction of new drugs, allogeneic transplantation was superior to autologous transplantation [98,99].”
BackgroundReduced-Intensity Stem Cell Transplantation
Antin, J. H. (2007) · Hematology · doi:10.1182/asheducation-2007.1.47 · Cited by 9
Yaqub, S., Ballester, G., & Ballester, O. (2013) · Cancer Investigation · doi:10.3109/07357907.2013.840382 · Cited by 9
Treatment of Multiple Myeloma: A Comprehensive Review
Kyle, R. A., & Rajkumar, S. V. (2009) · Clinical Cancer Reviews · doi:10.3816/ccr.2009.n.008 · Cited by 9
Induction Therapy for Newly Diagnosed Multiple Myeloma
Lonial, S., & Miguel, J. F. S. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0005 · Cited by 8
Cellular immunotherapy for plasma cell myeloma
Garfall, A. L., Vogl, D. T., Weiss, B. M., & Stadtmauer, E. A. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.54 · Cited by 8
Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: What Place, If Any?
Giralt, S., & Koehne, G. (2013) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-013-0185-y · Cited by 8
Salit, R. B., & Bishop, M. R. (2011) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2011.03.010 · Cited by 8
Jankowski, M., Dyszkiewicz-Konwińska, M., Budna, J., Knap, S., Bryja, A., Borys, S., Kranc, W., Magas, M., Ješeta, M., Bukowska, D., et al. (2018) · Medical Journal of Cell Biology · doi:10.2478/acb-2018-0005 · Cited by 8
Multiple Myeloma and Related Disorders
Rajkumar, S. V., & Dispenzieri, A. A. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00104-1 · Cited by 9
Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma
Bruno, B., Giaccone, L., Sorasio, R., & Boccadoro, M. (2009) · Seminars in Hematology · doi:10.1053/j.seminhematol.2009.02.001 · Cited by 12
Self-citationBruno, B., Auner, H. W., Gahrton, G., Garderet, L., Festuccia, M. B., Ladetto, M., Lemoli, R. M., Massaia, M., Morris, C., Palumbo, A. P., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1131278 · Cited by 9
“institutions.[6,7] This review is focused on the current”
BackgroundSelf-citationKawamura, K., Ikeda, T., Hagiwara, S., Mori, T., Shinagawa, A., Nishiwaki, K., Ohashi, K., Kubonishi, S., Fukuda, T., Ito, T., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2016.1154958 · Cited by 8
Multiple Myeloma and Related Disorders
Rajkumar, S. V., & Dispenzieri, A. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00101-8 · Cited by 8
Progress in allogeneic transplantation for multiple myeloma
Gahrton, G. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01495.x · Cited by 7
“Bruno 2007 (10) 58 Mycophenolate moffetil + Cyclosporin nr 43% 64% 32%”
BackgroundAoki, T., Kasai, M., Harada, Y., Matsubara, E., Morishita, T., Suzuki, T., Tsujita, M., Goto, N., Katayama, A., Watarai, Y., et al. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1355-3 · Cited by 7
“Some previous studies reported improved progression-free survival (PFS) and overall survival (OS) after this treatment [9–12], whereas recent reports showed no benefit for RIC alloHSCT as first-line therapy for MM [13–16].”
ResultUnrelated stem cell transplantation for patients with multiple myeloma
Kröger, N. M. (2010) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32833e5b01 · Cited by 7
Allogeneic stem cell transplantation in multiple myeloma: is there still a place?
Liberatore, C., Fioritoni, F., & Ianni, M. D. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1402106 · Cited by 10
Recent trends in the management of newly diagnosed multiple myeloma
Reece, D. E. (2009) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32832e3154 · Cited by 7
Afrough, A., Alsfeld, L. C., Milton, D. R., Delgado, R., Popat, U., Nieto, Y. L., Kebriaei, P., Oran, B., Saini, N. Y., Srour, S. A., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.05.023 · Cited by 8
Holstein, S. A., Suman, V. J., Owzar, K., Santo, K., Benson, D. M., Shea, T. C., Martin, T. G., Magalhaes-Silverman, M. D., Isola, L. M., Vij, R., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.03.028 · Cited by 7
“Biol Blood Marrow Transplant 2014; 20(8): 1183–1189.”
The Principles and Overview of Autologous Hematopoietic Stem Cell Transplantation
Vaughan, W. P., Seshadri, T., Bridges, M., & Keating, A. (2008) · Cancer treatment and research · doi:10.1007/978-0-387-78580-6_2 · Cited by 7
Multiple Myeloma: Biology, Standard Therapy, and Transplant Therapy
Gertz, M. A., Ghobrial, I. M., & Luc-Harousseau, J. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.10.006 · Cited by 7
Allogeneic Stem Cell Transplantation
Lacy, M. Q. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8520-9_11 · Cited by 7
Reduced intensity allogeneic stem cell transplantation in multiple myeloma
William, I. B. (2007) · Frontiers in bioscience · doi:10.2741/2395 · Cited by 7
Metadata
- Authors
- Bruno, B., Rotta, M., Patriarca, F., Mordini, N., Allione, B., Carnevale-Schianca, F., Giaccone, L., Sorasio, R., Omedè, P., Baldi, I., Bringhen, S., Massaia, M., Aglietta, M., Levis, A., Gallamini, A., Fanin, R., Palumbo, A., Storb, R., Ciccone, G., & Boccadoro, M.
- Affiliations
- Azienda Ospedaliero Universitaria San Giovanni Battista (IT)
- University of Udine (IT)
- Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo (IT)
- Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo (IT)
- Candiolo Cancer Institute (IT)
- University of Washington (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-03-15
- Volume
- 356
- Issue
- 11
- Pages
- 1110-1120
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2010766702
- Semantic Scholar
- 67383c7f6bdb3318b2667d1aad826b28d4117193
- Cited by
- 501
- References
- 35
- Citations by year
- 2025: 3 · 2024: 8 · 2023: 11 · 2022: 10 · 2021: 14 · 2020: 16 · 2019: 13 · 2018: 16 · 2017: 26 · 2016: 22 · 2015: 34 · 2014: 23 · 2013: 43 · 2012: 33
- FWCI
- 40.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System (University of Udine) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- National Cancer Institute (CA 78902, P01CA078902)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- multiple myeloma, allogeneic stem cell transplantation, autologous stem cell transplantation, matched sibling donor, graft-versus-host disease, overall survival, event-free survival, complete remission, non-relapse mortality, newly diagnosed multiple myeloma
- MeSH terms
- Adult, Aged, Female, Follow-Up Studies, Graft vs Host Disease, Histocompatibility Testing, Humans, Male, Middle Aged, Multiple Myeloma, Transplantation, Autologous, Transplantation, Homologous, Multivariate Analysis, Survival Analysis, Hematopoietic Stem Cell Transplantation, Transplantation Conditioning, Siblings
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.